Tag: neck

Tumor-Infiltrating Lymphocyte Therapy Market Gains Momentum with Expanding Oncology Applications | DelveInsight

Over the last ten years, cell-based immunotherapy has emerged as a promising approach for treating solid tumors. Several companies, including Iovance Biotherapeutics, Obsidian Therapeutics,...

Leatt Corp Announces Share Repurchase Program

CAPE TOWN, South Africa, Aug. 12, 2025 /PRNewswire/ -- Leatt Corporation (OTCQB: LEAT), a leading developer and marketer of head-to-toe protective equipment for MOTO,...

Theravance Biopharma, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

YUPELRI® (revefenacin) net sales of $66.3 million, recognized by Viatris, increased 22% year-over-year1Pivotal Phase 3 CYPRESS study enrollment on track to complete by late...

If you purchased any Pork product in the United States from June 28, 2014, through June 30, 2018, for business use in commercial food...

MINNEAPOLIS, Aug. 11, 2025 /PRNewswire/ -- A Settlement has been reached in a class action antitrust lawsuit filed on behalf of Commercial and Institutional...

Data Published in The Laryngoscope shows INO-3107 Resulted in Long-Term Surgery Reduction in Recurrent Respiratory Papillomatosis (RRP)

Retrospective trial showed Overall Response Rate (ORR) improved to 86% at the end of the second 12-month period (Year 2) compared to 72% observed...

Nyxoah Receives Approval from FDA for Genio® System for the Treatment of Obstructive Sleep Apnea

INSIDE INFORMATION
REGULATED INFORMATION

Nyxoah Obtient l’Autorisation de la FDA pour le Système Genio® Destiné au Traitement de l’Apnée Obstructive du Sommeil

INFORMATIONS PRIVILÉGIÉES
INFORMATIONS RÉGLEMENTÉES

Heartland Physio Unveils The R.E.A.L. Recovery Experience for Singapore’s Active Professionals

A personalised, root-cause approach that challenges one-size-fits-all physiotherapy.

A personalised, root-cause approach that challenges one-size-fits-all physiotherapy.

Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update

– LOQTORZI net revenue was $10.0 million, a 36% increase over Q1 2025 –

CLK Inhibitors Market Poised for Growth as Demand Rises in Oncology and Musculoskeletal Disorders | DelveInsight

The CLK inhibitors market is projected to expand in the coming years, driven by a rising incidence of cancer diagnoses, growing awareness of these...

CLK Inhibitors Market Poised for Growth as Demand Rises in Oncology and Musculoskeletal Disorders | DelveInsight

The CLK inhibitors market is projected to expand in the coming years, driven by a rising incidence of cancer diagnoses, growing awareness of these...

Alphamab Oncology Announces IND Application for Innovative PD-L1/αvβ6 Bispecific ADC JSKN022 was Officially Accepted by CDE

SUZHOU, China, Aug. 4, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the Investigational New Drug (IND) application for JSKN022, an independently...

Leatt Announces Date of Second Quarter 2025 Results Conference Call and Webcast

CAPE TOWN, South Africa, Aug. 1, 2025 /PRNewswire/ -- Leatt Corporation (OTCQB: LEAT), a leading developer and marketer of head-to-toe protective gear for a...

Coherus Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025

REDWOOD CITY, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Coherus, Coherus Oncology or the Company, Nasdaq: CHRS), today announced that its second quarter 2025 financial results will be released after market close on Thursday, August 7, 2025. Starting at 5:00 p.m. EDT on August 7, 2025, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update.

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Comments

This field is for validation purposes and should be left unchanged.

HomeTagsNeck

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Phreesia, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PHR

Canadian Employers Invited to Create 10,000 New Opportunities Through National Inclusive Hiring Campaign

GoHealth, Inc. to strengthen its position ahead of AEP 2026 through Restructuring Process supported by key stakeholders

Tag: neck

Tumor-Infiltrating Lymphocyte Therapy Market Gains Momentum with Expanding Oncology Applications | DelveInsight

Leatt Corp Announces Share Repurchase Program

Theravance Biopharma, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

If you purchased any Pork product in the United States from June 28, 2014, through June 30, 2018, for business use in commercial food...

Data Published in The Laryngoscope shows INO-3107 Resulted in Long-Term Surgery Reduction in Recurrent Respiratory Papillomatosis (RRP)

Nyxoah Receives Approval from FDA for Genio® System for the Treatment of Obstructive Sleep Apnea

Nyxoah Obtient l’Autorisation de la FDA pour le Système Genio® Destiné au Traitement de l’Apnée Obstructive du Sommeil

Heartland Physio Unveils The R.E.A.L. Recovery Experience for Singapore’s Active Professionals

Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update

CLK Inhibitors Market Poised for Growth as Demand Rises in Oncology and Musculoskeletal Disorders | DelveInsight

CLK Inhibitors Market Poised for Growth as Demand Rises in Oncology and Musculoskeletal Disorders | DelveInsight

Alphamab Oncology Announces IND Application for Innovative PD-L1/αvβ6 Bispecific ADC JSKN022 was Officially Accepted by CDE

Leatt Announces Date of Second Quarter 2025 Results Conference Call and Webcast

Coherus Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us